Generate Biomedicines Inc (NASDAQ:GENB) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Generate Biomedicines Inc (NASDAQ:GENB) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $25.40.

Several brokerages recently weighed in on GENB. Morgan Stanley raised their target price on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Wall Street Zen upgraded shares of Generate Biomedicines from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Finally, HC Wainwright upped their price target on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, May 8th.

Generate Biomedicines Price Performance

GENB opened at $14.00 on Monday. The business has a 50 day moving average price of $14.36. The firm has a market capitalization of $1.79 billion and a P/E ratio of -13.08. Generate Biomedicines has a 1-year low of $11.00 and a 1-year high of $18.18.

Generate Biomedicines (NASDAQ:GENB) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.